NEJM -- Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

CAMPATHがMSに、IFNbetaよりも効くそうです。
でも、免疫応答を下げることの副作用も、出てしまう。
甲状腺炎の割合がCAMPATHのほうでかなり高いですが、MSのほうが重篤だろうので、トレードオフが許容されるのかな。

NEJM -- Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

Alemtuzumab significantly reduced the rate of sustained accumulation of disability, as compared with interferon beta-1a (9.0% vs. 26.2%; hazard ratio, 0.29; 95% confidence interval [CI], 0.16 to 0.54; P<0.001) color="#ff0000">0.10 vs. 0.36; hazard ratio, 0.26; 95% CI, 0.16 to 0.41; P<0.001). p="0.005)." p="0.02)." color="#ff0000">23% vs. 3%] and immune thrombocytopenic purpura [3% vs. 1%]) and infections (66% vs. 47%). There were no significant differences in outcomes between the 12-mg dose and the 24-mg dose of alemtuzumab.